Renaming non-alcoholic fatty liver disease: from metabolic dysfunction-associated fatty liver heterogeneity to "different treatment for the same disease"
-
摘要: 关于非酒精性脂肪性肝病(NAFLD)更名为代谢功能障碍相关脂肪肝(MAFLD/MASLD)近两年来争议不断，期间大数据研究结果证明了NAFLD的时代局限性。重新审视命名法，可以正确认识NAFLD关键致病因素、了解其异质性及不同临床表型。目前NAFLD药物疗法临床应答率不高，通过分析其异质性，结合中医“同病异治”理论为临床诊断、研究、治疗NAFLD提供参考。Abstract: The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MAFLD) has been controversial for the last two years, during which the results of big data studies have proved the age-old limitations of NAFLD. Revisiting the nomenclature will allow for a proper understanding of the key causative factors of NAFLD, and an appreciation of its heterogeneity and different clinical phenotypes. The clinical response rate of NAFLD drug therapy is not high.By analyzing its heterogeneity and combining it with the theory of "different treatment for the same disease" in traditional Chinese medicine, we can provide references for clinical diagnosis, research, and treatment of NAFLD.
-
-
[1] Kuchay MS, Misra A. From non-alcoholic fatty liver disease(NAFLD)to metabolic-associated fatty liver disease(MASLD): A journey over 40 years[J]. Diabetes Metab Syndr, 2020, 14(4): 695-696. doi: 10.1016/j.dsx.2020.05.019
[2] Wong VW, Ekstedt M, Wong GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79(3): 842-852. doi: 10.1016/j.jhep.2023.04.036
[3] Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919. doi: 10.1007/s12072-020-10094-2
[4] Huang J, Kumar R, Wang M, et al. MASLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?[J]. J Hepatol, 2020, 73(5): 1265-1267. doi: 10.1016/j.jhep.2020.06.016
[5] Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40(9): 2082-2089. doi: 10.1111/liv.14548
[6] Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition?[J]. J Hepatol, 2023.
[7] Rich NE, Oji S, Mufti AR, et al. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 198-210. e2. doi: 10.1016/j.cgh.2017.09.041
[8] Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity[J]. World J Hepatol, 2021, 13(11): 1584-1610. doi: 10.4254/wjh.v13.i11.1584
[9] Martin-Grau M, Monleon D. Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease[J]. World J Clin Cases, 2023, 11(6): 1236-1244. doi: 10.12998/wjcc.v11.i6.1236
[10] Valibeygi A, Davoodi A, Dehghan A, et al. Dietary inflammatory index(DⅡ)is correlated with the incidence of non-alcoholic fatty liver disease(NAFLD): Fasa PERSIAN cohort study[J]. BMC Nutr, 2023, 9(1): 84. doi: 10.1186/s40795-023-00738-5
[11] 袁乙富, 曹勤, 蒋元烨. 饮食行为与非酒精性脂肪性肝病的关系[J]. 临床肝胆病杂志, 2023, 39(2): 401-407. doi: 10.3969/j.issn.1001-5256.2023.02.024
[12] 王俊俊, 蔡晓波, 陆伦根. 胆汁酸与非酒精性脂肪性肝病的关系[J]. 临床肝胆病杂志, 2023, 39(5): 1166-1171. doi: 10.3969/j.issn.1001-5256.2023.05.026
[13] Bauer KC, Littlejohn PT, Ayala V, et al. Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective[J]. Gastroenterology, 2022, 162(7): 1858-1875. e2. doi: 10.1053/j.gastro.2022.01.058
[14] De A, Mehta M, Singh P, et al. Lean Indian patients with non-alcoholic fatty liver disease(NAFLD)have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD[J]. Int J Obes(Lond), 2023, 47(10): 986-992. doi: 10.1038/s41366-023-01346-w
[15] Shao L, Liu J, Song Y, et al. Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease(MAFLD)[J]. Clin Chim Acta, 2023, 538: 203-210. doi: 10.1016/j.cca.2022.12.014
[16] An SM, Cho SH, Yoon JC. Adipose Tissue and Metabolic Health[J]. Diabetes Metab J, 2023, 47(5): 595-611. doi: 10.4093/dmj.2023.0011
[17] Feng X, Xuan R, Dong Y, et al. Changes in Clinical Manifestations Due to AFLD Retyping Based on the New MAFLD Criteria: An Observational Study Based on the National Inpatient Sample Database[J]. Diagnostics(Basel), 2023, 13(3): 488.
[18] Zachou K, Azariadis K, Lytvyak E, et al. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease[J]. JHEP Rep, 2023, 5(8): 100778. doi: 10.1016/j.jhepr.2023.100778
[19] 李非, 沈云峰. 表观遗传调控在NAFLD发生发展中的作用[J]. 南昌大学学报(医学版), 2023, 63(1): 88-91. https://www.cnki.com.cn/Article/CJFDTOTAL-JXYB202301017.htm
[20] Kountouras J, Kazakos E, Polyzos SA, et al. Potential impact of trained innate immunity on the pathophysiology of metabolic dysfunction-associated fatty liver disease[J]. Clin Immunol, 2023, 256: 109776. doi: 10.1016/j.clim.2023.109776
[21] Sharma D, Mandal P. NAFLD: genetics and its clinical implications[J]. Clin Res Hepatol Gastroenterol, 2022, 46(9): 102003. doi: 10.1016/j.clinre.2022.102003
[22] 夏安亮, 孙倍成. 巨噬细胞参与非酒精性脂肪性肝病的研究进展[J]. 南京医科大学学报(自然科学版), 2023, 43(10): 1456-1463. doi: 10.7655/NYDXBNS20231020
[23] Chan MM, Daemen S, Beals JW, et al. Steatosis drives monocyte-derived macrophage accumulation in human metabolic dysfunction-associated fatty liver disease[J]. JHEP Rep, 2023, 5(11): 100877. doi: 10.1016/j.jhepr.2023.100877
[24] 姜佳楠, 巩艳, 刘唯正, 等. 饮酒和代谢相关因素对代谢性脂肪肝发生重度纤维化的影响[J]. 解放军医学院学报, 2023, 44(7): 780-786. https://www.cnki.com.cn/Article/CJFDTOTAL-JYJX202307011.htm
[25] Pugliese N, Alfarone L, Arcari I, et al. Clinical features and management issues of NAFLD-related HCC: what we know so far[J]. Expert Rev Gastroenterol Hepatol, 2023, 17(1): 31-43. doi: 10.1080/17474124.2023.2162503
[26] Badmus OO, Hinds TD Jr, Stec DE. Mechanisms Linking Metabolic-Associated Fatty Liver Disease(MAFLD)to Cardiovascular Disease[J]. Curr Hypertens Rep, 2023, 25(8): 151-162. doi: 10.1007/s11906-023-01242-8
[27] Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD[J]. Hepatol Int, 2023, 17(4): 773-791. doi: 10.1007/s12072-023-10543-8
[28] Baratta F, D'Erasmo L, Bini S, et al. Heterogeneity of non-alcoholic fatty liver disease(NAFLD): Implication for cardiovascular risk stratification[J]. Atherosclerosis, 2022, 357: 51-59. doi: 10.1016/j.atherosclerosis.2022.08.011
[29] 杨梦茹, 韩睿. 非酒精性脂肪性肝病与慢性肾病关系的研究进展[J]. 临床肝胆病杂志, 2022, 38(11): 2586-2591. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD202211030.htm
[30] Sun DQ, Targher G, Byrne CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr, 2023, 12(3): 386-403. doi: 10.21037/hbsn-22-421
[31] Tsutsumi T, Nakano D, Hashida R, et al. The Inter-Organ Crosstalk Reveals an Inevitable Link between MASLD and Extrahepatic Diseases[J]. Nutrients, 2023, 15(5): 1123. doi: 10.3390/nu15051123
[32] 靳睿, 王晓晓, 刘峰, 等. 非酒精性脂肪性肝病的药物治疗进展[J]. 临床肝胆病杂志, 2022, 38(7): 1634-1640. doi: 10.3969/j.issn.1001-5256.2022.07.033
[33] Teng YX, Xie S, Guo PP, et al. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges[J]. J Clin Transl Hepatol, 2022, 10(5): 955-964. doi: 10.14218/JCTH.2021.00586
[34] Francque SM. Towards precision medicine in non-alcoholic fatty liver disease[J]. Rev Endocr Metab Disord, 2023, 24(5): 885-899. doi: 10.1007/s11154-023-09820-6
[35] Valenzuela-Vallejo L, Sanoudou D, Mantzoros CS. Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease[J]. J Pers Med, 2023, 13(5): 830. doi: 10.3390/jpm13050830
[36] Valenzuela-Vallejo L, Mantzoros CS. Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease(FLD)[J]. Metabolism, 2022, 134: 155246. doi: 10.1016/j.metabol.2022.155246
[37] 张淮, 郑明华. MASLD高危人群的筛查和分层管理[J]. 实用肝脏病杂志, 2023, 26(4): 463-466. doi: 10.3969/j.issn.1672-5069.2023.04.003
[38] 张悦, 粟兴洋, 谢静怡, 等. 《欧洲肝病学会临床实践指南: 评估肝脏疾病严重程度及预后的无创检测(2021年更新)》摘译[J]. 临床肝胆病杂志, 2021, 37(11): 2550-2554. doi: 10.3969/j.issn.1001-5256.2021.11.013
[39] 田爱平, 杨永峰. 非酒精性脂肪性肝病诊断——病理的重要性[J]. 临床肝胆病杂志, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[40] Chua D, Low ZS, Cheam GX, et al. Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MASLD Paradigm[J]. Int J Mol Sci, 2022, 23(23): 14762. doi: 10.3390/ijms232314762
[41] Gatzios A, Rombaut M, Buyl K, et al. From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights[J]. Biomedicines, 2022, 10(1): 161. doi: 10.3390/biomedicines10010161
[42] 马晓月, 李钦钦, 陆华贞, 等. 非酒精性脂肪肝动物模型及细胞模型研究进展[J]. 中国比较医学杂志, 2023, 33(6): 120-127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGDX202306017.htm
[43] Benegiamo G, von Alvensleben GVG, Rodríguez-López S, et al. The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression[J]. J Exp Med, 2023, 220(4): e20221738. doi: 10.1084/jem.20221738
[44] 蔡珊珊, 杨嘉恩, 梁惠卿. 非酒精性脂肪性肝病"同病异证"临床指标研究进展[J]. 中国中医药信息杂志, 2020, 27(1): 137-140. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202001031.htm
[45] 牛作虎, 段绍杰, 陈佳良, 等. 非酒精性脂肪性肝病患者肝纤维化与舌象特征的关系[J]. 中国中西医结合消化杂志, 2022, 30(10): 734-738. doi: 10.3969/j.issn.1671-038X.2022.10.10
[46] 张成, 王玉光, 闫世艳. 主方案伞式设计在中医药临床研究中的应用[J]. 北京中医药, 2023, 42(5): 487-490. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO202305007.htm
[47] 张浩然, 李毓秋, 田琪, 等. 基于LC-MS技术非酒精性脂肪肝病痰湿证大鼠肝脏的脂质组学分析[J]. 环球中医药, 2023, 16(10): 1959-1966. doi: 10.3969/j.issn.1674-1749.2023.10.005
[48] 李玲, 金华仙, 刘超, 等. 健脾调脂饮联合阿托伐他汀在非酒精性脂肪肝中的疗效分析[J]. 中国中西医结合消化杂志, 2023, 31(6): 445-450. doi: 10.3969/j.issn.1671-038X.2023.06.10
[49] 黄超原, 李炜, 程轶敏, 等. 基于中西医病证特点的非酒精性脂肪性肝病模型分析[J]. 中药药理与临床, 2023, 39(1): 78-85. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL202301015.htm
[50] Eslam M, Sanyal AJ, George J, et al. MASLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. doi: 10.1053/j.gastro.2019.11.312
[51] 李旭辉, 范建高. 非酒精性脂肪性肝病更名代谢相关脂肪性肝病的争议[J]. 肝脏, 2023, 28(5): 505-507. doi: 10.3969/j.issn.1008-1704.2023.05.001
[52] 杨蕊旭, 范建高. 非酒精性脂肪性肝病[J]. 肝脏, 2023, 28(1): 22-25. https://www.cnki.com.cn/Article/CJFDTOTAL-ZUAN202308004.htm
-
计量
- 文章访问数: 68
- 施引文献: 0
下载: